Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
about
Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolutionClinical implications of the molecular genetics of chronic lymphocytic leukemiaPersonalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistanceResistance and gain-of-resistance phenotypes in cancers harboring wild-type p53The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemiaClinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyondCIViC databaseTP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without ImmunotherapyPredicting survival in head and neck squamous cell carcinoma from TP53 mutation.ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy.Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we goTP53 Staining in Tissue Samples of Chronic Lymphocytic Lymphoma Cases: An Immunohistochemical Survey of 51 CasesPredicting survival in chronic lymphocytic leukemia.Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemiaDetection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.The genomic landscape of chronic lymphocytic leukemia: clinical implications.The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes.An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases.Telomere status in chronic lymphocytic leukemia with TP53 disruption.Molecular pathogenesis of chronic lymphocytic leukemia.Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program StudyThe spectrum of genetic defects in chronic lymphocytic leukemia.A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes.The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years.Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive diseaseThe role of TP53 network in the pathogenesis of chronic lymphocytic leukemia.Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial.Loss of p53 and altered miR15-a/16-1MCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells.TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing.Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses.
P2860
Q26823586-C51F41D3-3A7F-4120-9082-6C1221AB2C24Q26830955-7B22DEE1-C5E4-4CC7-BCB1-8FC2EAFDCA2FQ26866517-F71BDF0C-0186-4EFE-BFED-5D8171926A88Q27006998-EC88537B-5163-4DAF-BF0A-E5DA81A85CC5Q27024411-CCF0496F-BBE7-4F29-834D-0EAE16071E88Q27027493-4DFC2608-3679-41DB-AFAF-FDE012DC9343Q27612411-8759E172-4ED6-4528-BFA8-2E73A3CC2E26Q27853024-0894AC57-C9FB-49A0-8400-6B39E5803868Q28077136-9F49C092-9E61-47C6-9816-B5807124E5CAQ30365539-B131AC37-8390-427C-AEC6-120EB4BB7F84Q30768193-E036D911-6F9D-4991-B751-C48B7FEA0F86Q30986040-F2CDC3E2-DA87-4969-8BEC-EE856C1CF826Q33419580-C8FC4355-2C9B-445E-AD2E-02BAB8C857F0Q33558740-4247D252-3E0F-41C3-A205-3CE5691CBDD1Q33595764-041C1860-942B-4F84-9883-7F837984BCB5Q33744997-5B598E36-FFA1-4BB1-BCB3-93EBC138F63CQ33747801-9DA54FC4-712B-4D48-AE53-177995B27037Q34257190-E9330A34-B23C-4385-A0C5-D4F93875ED2FQ34453174-6DF6164D-9886-4EBA-B870-0D40FFF8D732Q34461989-BE3618F6-8A09-429E-89EB-CE89B85F0378Q34710882-E4B40039-4BB7-4535-A1FE-5FED92F052E2Q35149661-B77EE554-EF22-4448-A76B-67F2ED8BF238Q35407650-75C8B7D5-A5A5-47AE-80B4-416CBDCEF036Q35643026-D2E104EF-4AB0-49EF-9F42-8A6053E69D53Q35978724-4A2D4A3F-B2F6-4F90-A2D2-364E7DC5A712Q36093789-5E7F9CCC-3D27-4185-A016-0B97D22322CCQ36290321-9E4C8651-1EB5-4C38-933C-B2C8922CB30DQ36395599-004E2ED0-68B5-42F4-8FBC-9C2CE01C846DQ36426587-B3EA5F6B-51FE-4DFA-9CE4-159C91A7AB9BQ36519986-C8C34245-37CC-41FF-8553-7A4519495D1EQ36579130-C720F9C2-7D43-43FF-9C43-D7E943B1861FQ36800105-73E2870C-30B3-4251-BD1B-47CA05F02EC2Q36826893-F14F8AE8-A5C1-4DDF-B236-EFA01E9C6F7DQ36884141-3020525E-E38B-405C-A9BE-C512C1D7AFB1Q36956179-0782E9EA-05D3-4D17-A7AF-142938462FFAQ37049035-76A41B7F-62E5-4478-A172-010A4E43A218Q37199470-994E84F6-EC5B-4F24-9303-BE473E26F441Q37251592-329F2A71-4239-4E7B-8209-E433EE5A439EQ37326100-202942B9-49D2-4484-9239-FE56176EC0AEQ37427124-D488A095-43C0-4E96-91F5-CEEC9B8EC1AB
P2860
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Mutational status of the TP53 ...... sults from the LRF CLL4 trial.
@ast
Mutational status of the TP53 ...... sults from the LRF CLL4 trial.
@en
Mutational status of the TP53 ...... sults from the LRF CLL4 trial.
@nl
type
label
Mutational status of the TP53 ...... sults from the LRF CLL4 trial.
@ast
Mutational status of the TP53 ...... sults from the LRF CLL4 trial.
@en
Mutational status of the TP53 ...... sults from the LRF CLL4 trial.
@nl
prefLabel
Mutational status of the TP53 ...... sults from the LRF CLL4 trial.
@ast
Mutational status of the TP53 ...... sults from the LRF CLL4 trial.
@en
Mutational status of the TP53 ...... sults from the LRF CLL4 trial.
@nl
P2093
P50
P921
P3181
P356
P1476
Mutational status of the TP53 ...... sults from the LRF CLL4 trial.
@en
P2093
David Gonzalez
David Oscier
Gareth J Morgan
Pilar Martinez
Rachel Wade
Sarah Hockley
Sue M Richards
P304
P3181
P356
10.1200/JCO.2010.32.0838
P407
P577
2011-06-01T00:00:00Z